LifeStance Health Group, Inc. (LFST)
OvervaluedFundamental
58
Price
$12.03
Market Cap
$4.57B
Part 1 · What the company is worth
Overview
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a multidisciplinary suite of mental health services, psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It also treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on September 19, 2026 with claude-haiku-4-5 — shared with all users
Its behavioral health division has been adding outpatient mental-health locations across the US, competing market by market with LifeStance for the same commercially insured patients.
A privately held multi-state outpatient psychiatry and therapy group with 80+ clinics plus telehealth, competing for the same insured US patients and the same clinicians as LifeStance's hybrid clinic model.
A private national psychiatry practice in network with more than 60 US insurers, competing directly for the insurance-covered psychiatry and medication-management visits that are LifeStance's core revenue.
Offers insurance-covered virtual therapy and psychiatry to US consumers and employers, competing for the same outpatient mental-health visits that LifeStance delivers by telehealth.
A private platform that puts independent US therapists and psychiatrists in network with commercial payors, competing with LifeStance both for patients looking for an in-network clinician and for the clinicians themselves.
Through BetterHelp it is the largest virtual therapy brand in the US and is moving from cash-pay to insurance coverage, meeting LifeStance on the same outpatient therapy demand.
Balance Sheet & Liquidity
Revenue
$1.58B
Trailing 12 months (through 6/30/2026)
Net Income
$51M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$110M
Total Equity
$1.52B
Total Liabilities
$683M
Current Ratio
1.38
Interest Coverage
7.75
Debt/EBITDA
7.21
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$8.76
Current Price
$12.03
Margin of Safety
-37.4%
Fair Value Range
$5.69 - $11.82
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
92.54
ROE
0.6%
P/B Ratio
3.11
P/FCF
26.43
Gross Margin
-
ROIC
3.3%
Profitability Radar
Value Creation (Economic Moat)
ROIC
3.3%
WACC
11.1%
ROIC − WACC
-7.8 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (13)
- EPS shows upward trend
- P/FCF 26.43
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Return on Tangible Assets
- Revenue Growth 5Y 30.4%
- Analyst Consensus 78% Buy
- Earnings Surprise avg 621.9%
- Earnings Quality (OCF/NI) 4.31
- Net Margin Trend 3.2% vs -1.2%
- Piotroski F-Score 7/9
Failed (11)
- Price CAGR 4.88%
- ROIC 3.2%
- P/B Ratio 3.11
- Operating Margin 4.9%
- CapEx intensity
- Debt/EBITDA
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 3.4%
- Share Dilution 26.2%
Unavailable (3)
- Gross Margin NaN%
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Strong financial health
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Issuing new shares, diluting ownership
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Kenneth Alan Burdick J.D. | Executive Chairman | 66 |
| Mr. David Patrick Bourdon | CEO & Director | 56 |
| Mr. Ryan Bruce McGroarty | CFO & Treasurer | 52 |
| Mr. Vukasin Paunovich | Chief Technology Officer | 53 |
| Mr. Ryan Pardo J.D. | Chief Legal Officer & Secretary | 48 |
| Ms. Ann Varanakis | Chief People Officer | 47 |
| Ms. Lisa Keise Miller | Chief Operating Officer & Principal Operating Officer | 51 |
| Ms. Monica Prokocki | Vice President of Investor Relations | - |
| Brooke Matthews | Director of Public Relations | - |
| Mr. Richard Hall | Chief Shared Services Officer | - |
Audit Risk
10
Board Risk
10
Compensation Risk
7
Shareholder Rights Risk
8
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-25
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-08-06
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-09-11
via SEC EDGAR
Income History
via SEC EDGAR
Latest News
Recent headlines for LFST, sourced from Markets Gazette.
- 2/25/2026NEUTRALLifeStance (LFST) Q4 2025 Earnings Call Transcript
The transcript for LifeStance Health Group, Inc.'s (LFST) Q4 2025 earnings call is now available. Investors and analysts have been keenly awaiting this document to gain in-depth insights into the company's financial performance for the period. While the specific content has not been disclosed in this announcement, the release of the transcript is a crucial event for market transparency. Market participants will now focus on analyzing management's statements, future projections, and responses to analyst questions to assess LifeStance's operational health and growth prospects. The market's reaction will hinge on the key metrics presented and the guidance provided.
via Markets Gazette